209 related articles for article (PubMed ID: 10779364)
1. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
De Clercq E
Mol Pharmacol; 2000 May; 57(5):833-9. PubMed ID: 10779364
[TBL] [Abstract][Full Text] [Related]
2. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication.
Egberink HF; De Clercq E; Van Vliet AL; Balzarini J; Bridger GJ; Henson G; Horzinek MC; Schols D
J Virol; 1999 Aug; 73(8):6346-52. PubMed ID: 10400726
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
Bridger GJ; Skerlj RT; Padmanabhan S; Martellucci SA; Henson GW; Struyf S; Witvrouw M; Schols D; De Clercq E
J Med Chem; 1999 Sep; 42(19):3971-81. PubMed ID: 10508445
[TBL] [Abstract][Full Text] [Related]
4. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
Hatse S; Princen K; Gerlach LO; Bridger G; Henson G; De Clercq E; Schwartz TW; Schols D
Mol Pharmacol; 2001 Jul; 60(1):164-73. PubMed ID: 11408611
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
[TBL] [Abstract][Full Text] [Related]
6. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
7. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.
Schols D; Esté JA; Henson G; De Clercq E
Antiviral Res; 1997 Aug; 35(3):147-56. PubMed ID: 9298754
[TBL] [Abstract][Full Text] [Related]
8. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
9. Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist.
Schols D
Verh K Acad Geneeskd Belg; 1999; 61(4):551-64. PubMed ID: 10500476
[TBL] [Abstract][Full Text] [Related]
10. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
Princen K; Hatse S; Vermeire K; Bridger GJ; Skerlj RT; De Clercq E; Schols D
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1135-9. PubMed ID: 14709250
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
12. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.
Esté JA; Cabrera C; De Clercq E; Struyf S; Van Damme J; Bridger G; Skerlj RT; Abrams MJ; Henson G; Gutierrez A; Clotet B; Schols D
Mol Pharmacol; 1999 Jan; 55(1):67-73. PubMed ID: 9882699
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry.
Princen K; Hatse S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2003 Jan; 51(1):35-45. PubMed ID: 12500303
[TBL] [Abstract][Full Text] [Related]
14. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.
De Clercq E
Mini Rev Med Chem; 2005 Sep; 5(9):805-24. PubMed ID: 16178723
[TBL] [Abstract][Full Text] [Related]
15. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100.
Labrosse B; Brelot A; Heveker N; Sol N; Schols D; De Clercq E; Alizon M
J Virol; 1998 Aug; 72(8):6381-8. PubMed ID: 9658078
[TBL] [Abstract][Full Text] [Related]
16. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.
Arakaki R; Tamamura H; Premanathan M; Kanbara K; Ramanan S; Mochizuki K; Baba M; Fujii N; Nakashima H
J Virol; 1999 Feb; 73(2):1719-23. PubMed ID: 9882387
[TBL] [Abstract][Full Text] [Related]
17. CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.
Klasse PJ; Rosenkilde MM; Signoret N; Pelchen-Matthews A; Schwartz TW; Marsh M
J Virol; 1999 Sep; 73(9):7453-66. PubMed ID: 10438835
[TBL] [Abstract][Full Text] [Related]
18. Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides.
Heveker N; Montes M; Germeroth L; Amara A; Trautmann A; Alizon M; Schneider-Mergener J
Curr Biol; 1998 Mar; 8(7):369-76. PubMed ID: 9545196
[TBL] [Abstract][Full Text] [Related]
19. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor.
Gerlach LO; Skerlj RT; Bridger GJ; Schwartz TW
J Biol Chem; 2001 Apr; 276(17):14153-60. PubMed ID: 11154697
[TBL] [Abstract][Full Text] [Related]
20. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents.
Scozzafava A; Mastrolorenzo A; Supuran CT
J Enzyme Inhib Med Chem; 2002 Apr; 17(2):69-76. PubMed ID: 12420752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
